ASX:NEUPharmaceuticals
Is Neuren Pharmaceuticals' (ASX:NEU) 5% Buyback Quietly Rewriting Its Capital Allocation Story?
Neuren Pharmaceuticals Limited (ASX:NEU) has announced a share buyback program, authorizing the repurchase and cancellation of up to 6,350,631 shares, or 5% of its 126,639,526 issued shares, with the program running until March 2, 2027.
The decision to retire repurchased shares reduces the share count over time, which can increase each remaining investor’s proportional ownership in the company.
We’ll now examine how Neuren’s decision to repurchase and cancel up to 5% of its shares may...